Updating the ATS/ERS Task Force Report on Outcomes for COPD Pharmacological Trials.

Mario Cazzola,Paola Rogliani,Peter J Barnes,Francesco Blasi,Bartolome Celli,Nicola A Hanania,Fernando J Martinez,Bruce E Miller,Marc Miravitlles,Clive P Page,Ruth Tal-Singer,Maria Gabriella Matera

American journal of respiratory and critical care medicine（2023）

引用 0|浏览43

暂无评分

摘要

Since the 'label-free' treatable traits approach is becoming an important step toward precision medicine, future clinical trials should focus on highly prevalent treatable traits, which will influence the choice of outcomes and markers to be considered. The use of the new tools, particularly combination endpoints, could help identify better the right patient to be treated with the new drugs.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要